Enorama Pharma Valuation

Is ERMA undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of ERMA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate ERMA's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate ERMA's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ERMA?

Key metric: As ERMA is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for ERMA. This is calculated by dividing ERMA's market cap by their current revenue.
What is ERMA's PS Ratio?
PS Ratio	17.2x
Sales	SEK 13.26m
Market Cap	SEK 227.98m

ERMA key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	16.5x
Enterprise Value/EBITDA	-7x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does ERMA's PS Ratio compare to its peers?

The above table shows the PS ratio for ERMA vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	12.1x
ENZY Enzymatica	8.8x	64.7%	SEK 388.4m
ORX Orexo	0.6x	11.3%	SEK 329.5m
CLBIO Corline Biomedical	5.9x	46.0%	SEK 138.0m
RLS RLS Global	33.1x	106.0%	SEK 35.6m
ERMA Enorama Pharma	17.2x	n/a	SEK 228.0m

Price-To-Sales vs Peers: ERMA is expensive based on its Price-To-Sales Ratio (17.2x) compared to the peer average (5.1x).

Price to Sales Ratio vs Industry

How does ERMA's PS Ratio compare vs other companies in the SE Pharmaceuticals Industry?

10 Companies	Price / Sales	Estimated Growth	Market Cap
SECARE Swedencare	2.9x	12.1%	US$665.76m
ORX Orexo	0.6x	11.3%	US$29.84m
INDEX InDex Pharmaceuticals Holding	2.7x	n/a	US$27.34m
PMED PEPTONIC medical	2.3x	n/a	US$8.45m

10 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: ERMA is expensive based on its Price-To-Sales Ratio (17.2x) compared to the Swedish Pharmaceuticals industry average (15.7x).

Price to Sales Ratio vs Fair Ratio

What is ERMA's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ERMA PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	17.2x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate ERMA's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Swedish Orphan Biovitrum

SEK 99.6b

An integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia.

SOBI

SEK 290.00

-3.4%

15.7%

AstraZeneca

UK£162.4b

A biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines.

AZN

UK£1,462.00

5.5%

9.8%

PMD Device Solutions

SEK 35.3m

A digital medical device company, develops and sells respiratory monitoring solutions in Ireland.

PMDS

SEK 1.36

4.6%

n/a